Medscape reports a link between nicotinamide and a lower risk of melanoma in patients with a prior skin cancer diagnosis. The finding arrives in a chemoprevention field where evidence has been accumulating for years but where definitive guidance has remained elusive.

Nicotinamide, the amide form of vitamin B3, has occupied a distinctive place in skin-cancer prevention research since the landmark ONTRAC trial published in the New England Journal of Medicine in 2015. That randomized, double-blind study showed that oral nicotinamide 500 mg twice daily for 12 months reduced the rate of new non-melanoma skin cancers — basal-cell and cutaneous squamous-cell carcinoma — by 23% in high-risk patients compared with placebo. The effect on melanoma incidence, the most lethal form of skin cancer, was never the primary endpoint, and whether the compound influences melanoma risk has stayed an open question since.

The new Medscape report now connects nicotinamide with reduced melanoma risk in the post-skin-cancer population — a cohort dermatologists manage closely, because a history of keratinocyte carcinoma is itself a recognized marker of elevated melanoma risk. Patients who have had one skin cancer are already candidates for intensified surveillance: regular full-body skin examinations, total-body photography in many practices, and aggressive counseling on photoprotection. A cheap, oral adjunct that modifies melanoma risk in this group would carry meaningful clinical weight.

The mechanistic rationale is well established in the literature. Nicotinamide is a precursor of nicotinamide adenine dinucleotide (NAD), a coenzyme depleted in keratinocytes by ultraviolet radiation. Replenishing NAD enhances DNA repair, moderates the inflammatory response to UV exposure, and supports skin barrier function — pathways relevant to all UV-driven skin malignancies, melanoma included. Unlike nicotinic acid, nicotinamide does not cause flushing, which has supported its tolerability profile in long-term oral use.

Dermatologists will want to read the underlying study design before translating this signal into practice. Observational associations between a supplement and cancer incidence are vulnerable to confounding — patients who take nicotinamide may differ systematically from those who do not in sun behavior, surveillance intensity, and socioeconomic factors. Whether the reported association comes from a randomized dataset, a prospective cohort, or a retrospective database analysis will determine how firmly it can be interpreted. Duration of exposure, dose, and the interval between the index skin cancer and melanoma diagnosis are the parameters that will interest prescribers most.

The distinction matters clinically. The ONTRAC data secured nicotinamide a place in several international guidelines as an adjunct for patients with frequent keratinocyte carcinomas, typically at 500 mg twice daily, with the caveat that benefit appeared to wane after discontinuation. An extension of that evidence to melanoma — a malignancy whose prevention currently rests almost entirely on behavioral and surgical measures — would be a genuine advance, but it raises the evidentiary bar. Melanoma outcomes are graded in stages, from localized disease through AJCC stage III and IV, and any prevention claim invites scrutiny against hard endpoints.

For now, clinicians fielding patient questions about vitamin B3 should separate what is proven from what is suggested. The keratinocyte-carcinoma benefit is supported by randomized data. The melanoma association reported by Medscape adds a new layer and will need corroboration, ideally in prospective work with adequate power to capture melanoma as a distinct endpoint.

How the field receives the full dataset — and whether it prompts a dedicated melanoma-prevention trial of nicotinamide — is the question that will shape whether this vitamin moves from adjunct to established chemopreventive agent.